ALS drug pulled from market in Canada, U.S. after failing late-stage clinical trial
[ad_1] Amylyx Pharmaceuticals said Thursday it will withdraw its amyotrophic lateral sclerosis (ALS) drug from the market in Canada and the U.S. following its failure in a late-stage clinical trial. The ALS drug, branded Albrioza in Canada and Relyvrio in the U.S.,…







